Cancer Tumor Profiling Market Research Reveals Strong 13.4% CAGR Outlook Through 2030

The field of cancer tumor profiling is rapidly advancing as precision medicine continues to transform oncology. This sector is attracting significant attention thanks to ongoing technological innovations and the increasing demand for more tailored cancer treatments. Below is a detailed overview of the market's expected growth, key players, segmentations, and recent developments shaping this dynamic industry.

Projected Growth and Market Size of the Cancer Tumor Profiling Industry
The cancer tumor profiling market is poised for substantial expansion over the coming years. Forecasts indicate the market will reach a valuation of $28.27 billion by 2030, growing at an impressive compound annual growth rate (CAGR) of 13.4%. This surge is driven by a rising need for precision oncology to guide treatment decisions, the broadening landscape of personalized cancer therapies, and escalating investment in translational research. In addition, the increased adoption of advanced sequencing technologies and a growing emphasis on predictive oncology diagnostics contribute heavily to this anticipated growth. Key market trends through the forecast period include the expanding use of multi-omics tumor profiling, wider uptake of targeted sequencing panels, incorporation of AI-powered biomarker analysis, more personalized treatment planning, and stronger focus on prognostic profiling.

The cancer tumor profiling market size has grown rapidly in recent years. It will grow from $14.97 billion in 2025 to $17.1 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to increasing utilization of tumor biopsy testing, expansion of oncology research programs, early clinical adoption of molecular stratification, growth of hospital-based profiling services, rising availability of advanced laboratory infrastructure.

Download a free sample of the cancer tumor profiling market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Factors Propelling Expansion in the Cancer Tumor Profiling Market
One primary factor fueling growth is the escalating demand for precision decision-making in oncology. Clinicians and researchers seek more accurate tumor profiles to tailor therapies effectively, which is pushing adoption of cutting-edge diagnostic tools.
Simultaneously, the ongoing development of personalized cancer treatments fosters market momentum. As therapies become increasingly specific to individual tumor characteristics, profiling technologies grow in importance as essential tools for treatment selection and monitoring.

Leading Industry Players in the Cancer Tumor Profiling Sector
Numerous prominent companies are actively shaping the landscape of the cancer tumor profiling market. These include global leaders such as F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., and Qiagen. Other notable participants are HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, and Strand Life Sciences. Additional influential companies include Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, OncoDNA, Strata Oncology Inc., RareCyte Inc., Inivata Limited, and Cepheid.
In a significant recent development, AbbVie Inc. acquired ImmunoGen, Inc., a US-based biotechnology firm specializing in antibody-drug conjugate therapeutics for cancer, in February 2024. This acquisition is aimed at enhancing AbbVie's R&D capabilities, diversifying its product portfolio, and accelerating growth in key therapeutic segments.

View the full cancer tumor profiling market report:
https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Detailed Market Segmentation and Forecast for the Global Cancer Tumor Profiling Industry
This market is categorized into several key segments based on cancer type, technology, process, and application areas.
By Cancer Type, it includes Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, and Other Cancer Types. Within these categories, subsegments provide further granularity-for example, Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) under Lung Cancer; Hormone Receptor-Positive, Triple-Negative, and HER2-Positive Breast Cancer types; Colon and Rectal Cancer under Colorectal Cancer; Localized and Advanced forms of Prostate Cancer; Cutaneous and Non-Cutaneous Melanoma; Epithelial and Non-Epithelial Ovarian Cancer; Gastric Adenocarcinoma and Gastrointestinal Stromal Tumors (GISTs) for Stomach Cancer; Exocrine Pancreatic Cancer and Neuroendocrine Tumors; Papillary, Follicular, and Medullary Thyroid Cancer; as well as Kidney, Bladder, Liver, and Esophageal cancers grouped under Other Cancer Types.
In terms of Technology, the market covers Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, and other emerging platforms.
Process classification includes Genomics, Proteomics, Epigenetics, and other specialized types.
Regarding Application, profiled tumor data is widely used in Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, and Research Applications.

This comprehensive segmentation illustrates the vast scope of cancer tumor profiling, catering to diverse cancer types and technological approaches while supporting multiple clinical and research-driven objectives.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.